Read our recent posts
- New Recommendation from FDA Advisory Committee: Using Rexulti to Treat Agitation Associated with Alzheimer’s Disease May 2, 2023
- Six Ways to Support Cognitive Health for Older Adults May 2, 2023
- The Cost Burdens of Diagnosing and Treating Alzheimer’s Disease: Alarming Issues for Patients, Providers and Payers Nationwide April 3, 2023
- Clinician Alert: Identify the Right Patients at the Right Time for Disease Modifying Therapies to Address Alzheimer’s Disease March 20, 2023
- Seven Ways to Care for Your Brain March 13, 2023
- FDA Approves Alzheimer’s Agent Leqembi Shortly After Release of Congressional Aduhelm Report February 22, 2023
- The Burden of Diagnosis: How physicians confront diagnosing Alzheimer’s disease with influx of patients seeking disease modifying therapies January 29, 2023
- FDA Approval of New Drug for Alzheimer’s Disease Underscores Need for DISCERN™ Accurate Diagnostic Testing Prior to Prescribing LEQEMBI™ and Finalizing Coverage January 11, 2023
- Honoring Caregivers, Patients and Families During Caregivers and Alzheimer’s Awareness Month November 28, 2022
- SYNAPS Dx Publishes First Autopsy-Confirmed Results for Identifying Alzheimer’s in Presence of Other Co-Morbid Pathologies Using DISCERN™ Test November 2, 2022
- Spotlighting Accurate, Early Diagnosis of Alzheimer’s Disease: World Alzheimer’s Month September 5, 2022
- SYNAPS Dx Opens High-Tech Laboratory Supporting Research & Commercialization of DISCERN, Highly Accurate, Minimally Invasive Alzheimer’s Disease Diagnostic Test August 9, 2022
- A Breakthrough in Diagnosing Alzheimer’s Disease August 1, 2022
- SYNAPS Dx Releases Autopsy-Confirmed Results for DISCERN Alzheimer’s Test MI Biomarker, Accurately Diagnoses Alzheimer’s in Presence of Other Co-Morbid Pathologies August 1, 2022
- SYNAPS Dx Showcases Autopsy-Confirmed Results for DISCERN Alzheimer’s Test MI Biomarker, For Identifying Alzheimer’s in Presence of Other Co-Morbid Pathologies July 19, 2022
- SYNAPS Dx Selects Dallas/Fort Worth Texas Markets as First Regions for National Commercialization of Highly Accurate Diagnostic Alzheimer’s Disease Test for Patients with Dementia Diagnosis July 12, 2022
- The “Longest Day” is June 21: Help Fight the Darkness of Alzheimer’s Disease Through Fundraising June 21, 2022
- Spotlight on Availability of First Skin Test for Accurate Diagnosis of Alzheimer’s Disease: June is Alzheimer’s & Brain Awareness Month June 17, 2022
- ISPOR Annual Conference: 90% of Physicians Follow Results of DISCERN, First Skin Test for Alzheimer’s Disease May 11, 2022
- May is Older Americans Month: Definitive Diagnosis of Alzheimer’s Disease Helps More Americans Get the Support They Need Sooner April 21, 2022